Bionano Genomics (BNGO) Cash from Investing Activities (2017 - 2026)

Bionano Genomics has reported Cash from Investing Activities for 10 years, with the latest figure at $5.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 138.8% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (down 44.4% YoY) and the FY2025 annual result came in at -$12.7 million, down 117.26% from the prior year.
• Cash from Investing Activities rose to $5.5 million in Q1 2026 per BNGO's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $47.6 million in Q1 2024 and troughed at -$55.4 million in Q4 2023.
• A 5-year average of $10.2 million and a median of $8.0 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 133283.33% in 2022, then slumped 576.94% in 2023.
• Over 5 years, Cash from Investing Activities stood at $11.6 million in 2022, then plunged by 576.94% to -$55.4 million in 2023, then surged by 105.41% to $3.0 million in 2024, then soared by 33.77% to $4.0 million in 2025, then surged by 36.12% to $5.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $5.5 million, $4.0 million, and -$4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.